The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK: